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fetal side effects. [7] [8] [9] [10] Although other compounds have been used for tocolysis, questions remain as to their efficacy and safety, [11] [12] [13] [14] Oxytocin is a potent stimulant of myometrial contractility. A role for this hormone and its receptor in human parturition has been postulated. [15] [16] [17] [18] [19] Atosiban (Antocin, R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ) is a selective oxytocin-vasopressin receptor antagonist capable of inhibiting oxytocin-induced uterine contractions in both animals 20 and women with preterm labor. [21] [22] [23] [24] The purpose of this study was to evaluate the efficacy and safety of atosiban in the treatment of patients in preterm labor.
Material and methods

Protocol.
Patients were eligible for participation if they met the following criteria: preterm labor with intact membranes, cervical dilatation of ≤3 cm, gestational age of 20 weeks to 33 weeks 6 days, live fetus(es), and provision of written informed consent. Gestational age was determined by the best clinical estimate available. The diagnosis of preterm labor required the presence of ≥4 uterine contractions over 30 minutes, each lasting at least 40 seconds, and documented cervical change. The cervical criteria were met when either of the following was present: (1) a single cervical examination demonstrating dilatation of 1 cm to <3 cm and effacement of at least 75% or dilatation of 3 cm with effacement of at least 50% or (2) multiple cervical examinations demonstrating a 1-cm increase in cervical dilatation or an increase in effacement of 50%.
Patients were excluded from participation if they had any of the following: fetal or placental abnormalities, fetal distress, suspected chorioamnionitis, maternal indications for delivery, urinary tract infection, and overt clinical manifestations of substance abuse. The study was approved by the institutional review boards of the participating institutions.
Patients were randomly assigned to receive intravenous therapy with atosiban or matching placebo for at least 1 hour. Assigned short-term treatment was planned for up to 48 hours, followed by maintenance therapy with the assigned treatment. Active drug and placebo were administered at the same volume and rate. Shortterm intravenous therapy began with a bolus of initial study drug (6.75 mg for atosiban) administered over 1 minute. This was followed immediately by an infusion of 300 µg/min of atosiban for 3 hours, then 100 µg/min of atosiban for up to 45 hours. Intravenous treatment was discontinued when uterine quiescence, progression of labor, or rupture of membranes occurred. Uterine quiescence was defined as either 12 consecutive hours of ≤4 contractions per hour (lasting ≥40 seconds) or 48 hours of intravenous infusion without progression of labor requiring the use of an alternate tocolytic. Labor was considered to have progressed and the patient became eligible for rescue tocolysis if either of the following occurred after at least 1 hour of observation during intravenous treatment: (1) cervical effacement ≥75% {≤0.5 cm) with no decrease in the frequency or intensity of contractions and continued cervical change (at least a 1-cm change in dilatation or effacement) or (2) cervical dilatation of ≥4 cm with a 1-cm increase since the last cervical examination. Patients could receive rescue therapy with an alternate tocolytic of the investigator's choice after discontinuation of study drug. To receive rescue therapy patients were to meet the criteria for progression of labor while receiving their assigned intravenous study drug. Atosiban was not used as rescue therapy for patients allocated to the placebo group. Patients who achieved uterine quiescence received maintenance therapy via a subcutaneous infusion of either atosiban or matching placebo. Maintenance therapy began as a subcutaneous infusion of 0.004 mL/min (30 µg/min for atosiban) to the end of the 36th week of gestation, the time of delivery, or the progression of labor necessitating an alternate tocolytic, whichever occurred first. Once maintenance had begun, alternate tocolytics were permitted only after a subsequent intravenous study drug infusion when progression of labor was observed. Home health care and daily nursing contact were provided to all patients.
Intravenous therapy for additional episodes of preterm labor was permitted. Other tocolytic agents were not permitted concomitantly with study drug. Antibiotic and corticosteroid therapy was allowed for standard clinical indications.
A computer-generated randomization schedule (according to permuted blocks of 6 with even allocation and stratification by center but not by gestational age) was used. Prenumbered randomization envelopes provided to the pharmacist at each study center were to be opened in sequential order. Study drugs were clear liquid solutions. Matching placebo consisted of the atosiban formulation minus the atosiban (5% mannitol solution) and was supplied in vials that appeared identical to those of the active agent. Investigators, study personnel, and monitors remained blinded throughout the study.
Outcomes and statistical methods. The primary end point was the time (days) to delivery or therapeutic failure (progression of labor necessistating an alternate tocolytic), whichever occurred first. Planned secondary end points were the percentages of patients who were successfully treated up to 24 hours, 48 hours, and 7 days after the start of acute intravenous therapy. Maternalfetal adverse events and infant outcomes at delivery also were assessed.
It was estimated that 250 patients in each treatment group would be required to provide 80% power to detect an atosiban-to-placebo ratio of 1.3 for the mean number of days from the start of study drug to delivery or thera-peutic failure (eg, 26 days vs 20 days). The estimates for the mean number of days from the start of study drug to delivery or therapeutic failure were based on the results of an atosiban dose-ranging study 23 and the Canadian preterm labor study. 6 Schoenfeld's method 25 was used for the determination of sample size (α = .05).
For efficacy, the primary intent-to-treat analyses were performed on the basis of all patients who received study drug. The attrition rate in this study was minimal (6%); therefore from a clinical perspective the results from the population of patients who received study drug are most meaningful. 26 However, intent-to-treat analyses including all patients randomized were performed. The results of the intent-to-treat analyses of both populations led to the same conclusion, but only the results for patients who received study drug are provided. The interval from start of treatment to delivery or therapeutic failure was analyzed with survival data analysis methods (log-rank test) and was stratified by center. 27 Cox's proportional-hazards model was used for exploratory multivariate analysis for this end point. Possible effects of alternate tocolytics given for reasons other than progression of labor were excluded by censoring observations at the time such agents were administered. Cochran-Mantel-Haenszel tests, stratified by center, were used to compare the percentages of patients who remained undelivered and had not used an alternate tocolytic at 24 hours, 48 hours, and 7 days. Logistic regression was used for exploratory multivariate analyses of these 3 end points. All tests were 2-sided with α = .05, with the exception of tests for interactions, which used α = .10. For the evaluation of safety, patients were classified according to the study drug they actually received; patients who inadvertently received both atosiban and placebo were placed in the atosiban group. Maternal-fetal adverse events are summarized according to the WHOART dictionary. 28 Information on the infants obtained at delivery is summarized with descriptive statistics.
For efficacy and safety end points, 2-sided 95% confidence intervals for the difference in percentages or means between treatment groups are provided as descriptive statistics. Summaries and results of analyses are presented on the basis of the gestational age at admission.
Results
Disposition of patients and baseline characteristics of the population. Five hundred thirty-one patients were enrolled and randomized to treatment at 37 study centers, and 501 received the study drug. Fifteen patients randomized to each treatment did not receive study drug for similar reasons. The most common reason was a post-randomization protocol exclusion that prohibited study treatment of patients in whom cervical dilatation had progressed beyond 3 cm before study drug could be prepared. Fig 1 displays a trial profile describing the disposition of patients. The baseline demographic and clinical characteristics of patients in both groups are displayed in Table I . The treatment groups were comparable for most baseline variables including race, maternal age, and parity. However, the mean gestational age on admission was statistically significantly greater for the placebo group than for the atosiban group, and there were nearly twice as many atosiban-treated patients enrolled at <26 weeks' gestation. Among patients enrolled at <26 weeks, the percentage who had advanced cervical status (modified Bishop score ≥4) was greater for those allocated to the atosiban group.
Effect of atosiban on primary and secondary outcomes.
The difference in time to delivery or therapeutic failure between atosiban and placebo was not statistically significant (median, 25.6 days; range, 0 to 115.5 days; vs 21.0 days; range, 0 to 110.7 days, respectively; P = .6). This is reflected in survival curves for the time to delivery or therapeutic failure (Fig 2) . Cox's proportional hazards modeling indicated a significant interaction (P < .10) between treatment and gestational age at entry, with results favoring atosiban at higher gestational ages (≥28 weeks) and placebo at lower gestational ages (<28 weeks). Because it was difficult in many cases to withhold rescue tocolytic therapy until protocol-specified criteria were met, 20% of the patients in each treatment group were censored in the primary analysis; most of them received an alternate tocolytic without meeting the strict definition of therapeutic failure specified in the protocol. A review of the censored cases revealed that the switch to an alternate tocolytic was frequently related to the lack of efficacy of the assigned treatment.
The proportions of patients who remained undelivered and had not used an alternate tocolytic at 24 hours, 48 hours, and 7 days were significantly greater in the atosiban group (Tables II and III) . Logistic regression analysis demonstrated statistically significant interactions between treatment and gestational age at entry (P < .10) for the 7-day and 48-hour end points. Atosiban was estimated to be superior to placebo for patients randomized at gestational ages of ≥25.5 weeks and ≥26.4 weeks, for the 7-day and 48-hour end points, respectively. For the 24-hour end point the interaction approached statistical significance.
Safety results. The mean duration of therapy was 15.9 days (SD, 20.60 days; range, 1 to 107 days) for the patients who received placebo and 18.7 days (SD, 19.92 days; range, 1 to 106 days) for the patients who received atosiban. Alternate tocolytics as rescue therapy were used in 42% of atosiban patients and 51% of placebo patients with adverse events that developed during the first 24 hours of the alternate tocolytic agent assigned to the study drug. Although the effects of rescue tocolytics were not added to the study drug effects in the efficacy assessments, rescue tocolytic effects were included in safety assessments of the study drug. For this reason, as well as because a high percentage of rescue was used in both study arms, the safety components of this study are referred to as "atosiban with or without rescue" and "placebo with or without rescue." Antibiotics (received by 52% of atosiban with or without rescue patients and 46% of placebo with or without rescue patients) and antepartum corticosteroids (received by 46% of atosiban with or without rescue patients and 51% of placebo with or without rescue patients) were not required by the protocol but were given according to study center criteria. Fifty-four percent of the atosiban with or without rescue infants who began therapy before 28 weeks received antenatal corticosteroids and 48% of the atosiban with or without rescue infants who began therapy at ≥28 weeks received antenatal corticosteroids, whereas 53% of the placebo with or without rescue infants who began therapy before 28 weeks and 52% of the placebo with or without rescue infants who began therapy at ≥28 weeks received antenatal corticosteroids. Only 20 (7%) of the atosiban with or without rescue infants and 12 (4%) of the placebo with or without rescue infants were delivered between 28 and 34 weeks' gestational age and 1 to 7 days after corticosteroid administration.
No maternal deaths occurred during the study or through the postpartum period. Six fetal deaths were reported during the study, 3 fetuses of 2 placebo with or without rescue patients and 3 fetuses of 3 atosiban with or without rescue patients.
Selected maternal-fetal adverse events are listed in Table IV . The incidences of adverse events in the 2 study groups were comparable, with the exception of a higher proportion of injection-site reactions in the atosiban with or without rescue group (Table IV) . Most of these injection site reactions occurred during maintenance therapy with the subcutaneous pump. Four percent of patients treated with placebo with or without rescue and 16% of patients treated with atosiban with or without rescue discontinued therapy because of adverse events; approximately half in each treatment group discontinued treatment as a result of injection-site reactions during the subcutaneous maintenance.
The number of infants delivered in the atosiban with or without rescue group was 288, and 295 infants were delivered in the placebo with or without rescue group. The rate of fetal-infant deaths was 4.5% (13/288) in the atosiban with or without rescue group and 1.7% (5/295) in the placebo with or without rescue group. Table V displays fetal-infant deaths according to gestational age at enrollment. An examination of the circumstances surrounding the infant deaths among patients in the atosiban with or without rescue group who were randomized before 26 weeks suggests that extreme prematurity and perinatal infection were common complications; most of these fetuses-infants had birth weights of <650 g, and 5 had no delivery room resuscitation. The perinatal death rate in this study was 2.1% for atosiban with or without rescue and 1.4% for placebo with or without rescue.
Infant outcomes for patients enrolled in the trial are summarized in Table VI . Infant outcome data generally were consistent with efficacy results. Because the proto- *Modified Bishop score is sum of dilatation score, as follows: 0, <l cm; 1, 1 cm to <3 cm; 2, 3 cm to <5 cm; 3, ≥5 cm; plus effacement score, as follows: 0, 0% to <40%; 1, 40% to <60%; 2, 60% to <80%; 3, ≥80%.
†Data on 1 subject in placebo group and 1 subject in atosiban group were missing for modified Bishop score in this gestational age category.
‡Data on 1 subject in placebo group and 2 subjects in atosiban group were missing for modified Bishop score in this gestational age category. col allowed alternate tocolytic agents as rescue therapy after only 1 hour of study drug infusion, all infants had the same probability of pregnancy prolongation. Infant outcomes for patients enrolled at ≥28 weeks were comparable between atosiban with or without rescue and placebo with or without rescue, whereas differences in birth weight and respiratory distress syndrome favored placebo with or without rescue at <28 weeks.
Comment
Treatment of preterm labor with tocolytic agents and corticosteroids has become standard obstetric practice. The delay in delivery afforded by tocolysis is thought to contribute to the beneficial effects of corticosteroid administration in reducing the incidence of respiratory distress syndrome, intraventricular hemorrhage, and perinatal mortality. 29, 30 Three different study designs could be used to test the efficacy of a new agent: (1) placebo-controlled trial, (2) equivalence trial (a comparison of 2 active agents), or (3) placebo with or without rescue trial. The efficacy of tocolysis in delaying delivery was established with placebo-controlled trials. However, this investigational approach is not acceptable to many clinicians who would not agree to participate in a trial requiring that tocolysis be withheld in a patient at risk for preterm delivery. An equivalence trial comparing atosiban with ritodrine to delay delivery for 48 hours was entertained but considered not feasible because of the infrequent use of ritodrine in the United States. The third option, a novel design in clinical trials of tocolysis, was to conduct a study in which patients who met a strict definition of premature labor were allowed to receive placebo treatment for at least 1 hour and thereafter permitted alternate tocolytics as "rescue therapy."
Two features of this clinical trial are noteworthy. First, although this trial is placebo controlled with regard to the primary efficacy end point (time to delivery or therapeutic failure), this study is not a placebo-controlled trial with respect to infant outcomes (or time to delivery) because all patients were permitted to receive "rescue therapy" after only 1 hour of study drug infusion (atosiban or placebo) if criteria for progression of labor were met. Second, the subgroup of patients with failure of assigned treatment with placebo who received an alternate tocolytic as "rescue therapy" are biologically different from the subgroup of patients with failure of assigned treatment with atosiban who received an alternate tocolytic as rescue therapy. These features have important implications for the interpretation of our results.
The placebo-controlled primary efficacy end point of this trial was the time elapsed between the beginning of treatment and delivery or therapeutic failure. Statistical significance for this end point was not achieved. However, an implicit assumption in the selection of this end point was that a tocolytic agent should be able to prolong pregnancy and prevent preterm birth. Regrettably, despite the use of a wide range of pharmacologic ap- proaches (ie, multiple β-adrenergic receptor agents, magnesium sulfate, prostaglandin synthase inhibitors, calcium channel blockers), there is little evidence that the goal can be achieved. Previous studies have demonstrated that short-term tocolysis with ritodrine can prolong pregnancy for up to 7 days. 6 However, parenteral administration of this drug is associated with a significant rate of side effects that appear to have limited its clinical utility. The observations reported here suggest that a similar prolongation of pregnancy can be accomplished with atosiban with a lower rate of maternal side effects. The consistent inability of tocolytic agents-regardless of their mechanism of action-to reduce the rate of preterm birth is a reflection that this strategy (tocolysis) addresses only one of the clinical manifestations of preterm parturition, uterine contractility, rather than the underlying physiologic process causing preterm labor and birth. 31 The clinical advantages of short-term prolongation of pregnancy (7 days) are related to the time gained either to allow administration of corticosteroids or to permit transfer of the patient to an institution with an intensive care nursery, or both of these, interventions that can reduce the risk of perinatal morbidity and mortality. 1 Tocolytic failure in the first days of therapy has a potentially worse prognosis for infant survival than failure after weeks of treatment. An examination of the survival curves for the primary end point (Fig 2) reveals that the curves are completely separated for at least the first 15 days of treatment and that the atosiban curve is above the placebo curve for approximately 45 days from the initiation of treatment. The results of the early end points of 24 hours, 48 hours, and 7 days are consistent with the early separation in the survival curves.
A significant interaction existed between treatment and gestational age at entry for the time to delivery or therapeutic failure and the proportion of patients who remained undelivered and did not receive an alternate tocolytic at 48 hours and 7 days after the start of treatment. Results favored atosiban over placebo for patients at higher gestational ages but not at lower gestational ages. For both the 48-hour and 7-day time points, an advantage of atosiban over placebo was observed at gestational ages of ≥28 weeks at admission. A possible explanation for this interaction is the existence of a different pathologic mechanism involved in preterm labor at different gestational ages. Specifically, the frequency of intrauterine infection, which renders tocolysis less effective, has been reported to be greater when the gestational age at presentation is lower. 32 It is noteworthy that in this study and others about 80% of enrolled patients were at ≥28 weeks' gestational age. Therefore most patients in preterm labor who are eligible for tocolysis are in the gestational age range at which there is benefit from atosiban.
The higher rate of fetal-infant deaths in the active treatment group deserves comment (Table V) . A greater number of patients who had a gestational age of <26 weeks and advanced preterm labor (as judged by the modified Bishop score) were allocated to the atosiban with or without rescue group. This unexpected imbalance may have accounted for the increased rate of fetalinfant deaths. Seven of the 10 infant deaths in the atosiban with or without rescue group were among patients enrolled at <24 weeks who delivered newborns with birth weights <650 g. Five of the these 10 infants who died did not receive any immediate delivery room resuscitation. Chorioamnionitis was diagnosed in 3 of 7 cases and may have played a role in the deaths. However, adverse effects caused by atosiban cannot be excluded. Since atosiban binds to vasopressin receptors, it could be argued that some of the adverse outcomes in infants exposed to atosiban may be the result of an altered physiologic fetal response to an insult. 33 Indeed, vasopressin secretion is part of the fetal homeostatic response to stress. 34 Could a potential antivasopressin effect have contributed to the poor outcomes among infants enrolled at <28 weeks? Several observations make this unlikely. First, both in the current study and in a randomized clinical trial of maintenance therapy, infants with the greatest exposure to atosiban had better perinatal outcomes when compared with outcomes of infants with the least exposure to atosiban 35 (data also on file with the R.W. Johnson Pharmaceutical Research Institute, Route 202, PO Box 300, Raritan, NJ 08869). Second, in the pooled analysis of 3 other active controlled studies (atosiban vs ritodrine, atosiban vs terbutaline, and atosiban vs salbutamol) there were twice as many fetal and infant deaths in infants exposed to β-sympathomimetics as in those exposed to atosiban (12/429 in the β-sympathomimetic group vs 6/404 in the atosiban group) 36 (data also on file with Ferring Pharmaceuticals, Malmo, Sweden). Third, standard toxicity studies in pregnant animals revealed no demonstrable adverse events at fetal antocin levels threefold higher than those observed in human fetuses 37 (data also on file with the R.W. Johnson Pharmaceutical Researach Institute). Last, no evidence of altered stress response was observed after short-term and long-term exposure of fetal sheep to atosiban. In these experiments animals were evaluated under fetal hypoxic stress conditions while receiving atosiban in quantities sufficient to produce plasma concentration levels equivalent to the highest concentrations observed in the human fetus during clinical tocolysis (Nathanielsz P. Personal communication).
Our trial demonstrates that atosiban is superior to placebo in delaying delivery for up to 7 days in preterm labor patients at ≥28 weeks' gestation. However, this raises the question as to why infant outcomes were not demonstrably better. A key methodologic aspect of this trial is that all patients in preterm labor who required tocolysis were allowed to receive it. Therefore infant outcomes cannot be expected to be different between the 2 study groups if the tocolytic effect of atosiban is equivalent to that of rescue tocolysis. Another aspect of the study design pertains to the evaluation of infant safety. A standard approach to examine safety is to determine the frequency of adverse events in patients who have been exposed to the agents under study. However, in an effort to understand unexpected adverse outcomes, investigators also tend to compare results between treatment subgroups defined by the response to the assigned treatment (ie, patients whose assigned treatment failed). Such post hoc analyses have limitations in placebo-controlled trials because response or failure with placebo has a different meaning from response or failure with an active agent. By design, placebo-controlled tocolytic trials with rescue therapy will create the impression of drug toxicity from the active treatment when treatment re- Many clinicians would interpret this as evidence that the patient was not in preterm labor (treatment subgroup 1). Alternatively, uterine contractility and cervical changes may continue, necessitating treatment with a tocolytic agent (treatment subgroup 2). These two treatment subgroups are clearly different because one group is in preterm labor and one is not. Patients allocated to atosiban (active) may also respond in either of two ways. Those who achieve uterine quiescence (treatment subgroup 3) are composed of a mixture of patients who are not in real preterm labor but have a placebo response and those in real preterm labor who have responded to atosiban. In patients without a response to atosiban (treatment subgroup 4) the initial trial of tocolysis failed. sponse subgroups are examined. Indeed, the subgroup of patients with active treatment failure will always have the worst perinatal outcomes (Fig 3) . The complication rate among infants in the atosiban failure subgroup (Fig  3, subgroup 4) should be higher than that of the placebo failure subgroup (Fig 3, subgroup 2) . With this study design the treatment subgroups are not comparable and infant outcomes will be different in each.
Atosiban therapy was well tolerated in both the mothers and the fetuses. The side effect profiles of atosiban and placebo were comparable (Table IV) , with the exception of a higher incidence of injection-site reactions during maintenance among patients receiving atosiban. Most of the injection-site reactions that occurred during maintenance therapy with the subcutaneous pump were minor. In some cases marked injection-site reactions led to discontinuation of therapy. The safety results associated with atosiban treatment compare favorably with published data on the β-sympathomimetics, including ritodrine, the only tocolytic agent approved in the United States. 38 The superiority of atosiban maternal-fetal safety compared with that of ritodrine has also been demonstrated in 2 randomized clinical trials. 23, 39 A significant difference between atosiban and β-sympathomimetics was observed in the occurrence of pulmonary edema 40 (data also on file with the R.W. Johnson Pharmaceutical Research Institute) in the atosiban development program. There were no cases of pulmonary edema when atosiban was the only tocolytic administered (0/1633), but there were 2 cases of pulmonary edema when a β-sympathomimetic was the only tocolytic administered (2/430).
The current classes of tocolytic agents are far from ideal because all available agents have documented serious side effects for either the mother or the infant, or both, and some may have fetal toxicity. For example, there is a growing concern about the safety of magnesium sulfate, probably the most widely used intravenous tocolytic agent used in the United States today. 41 These concerns emanate from the results of the MAGNET trial, 42, 43 as well as the Collaborative Eclampsia Trial of magnesium versus diazepam. 44 In this latter trial patients with eclampsia treated with magnesium sulfate had a perinatal mortality that was twofold higher than that in patients with eclampsia who were randomized to magnesium and delivered before receiving the drug (25% vs 12%). Other factors may be involved in the adverse outcomes reported in association with the administration of magnesium sulfate, but a toxic effect of magnesium cannot be excluded.
In this trial the treatment of patients in preterm labor with atosiban resulted in prolongation of pregnancy for up to 7 days for those at a gestational age ≥28 weeks with a low rate of maternal-fetal adverse effects. In addition, at a gestational age ≥28 weeks, infant morbidity and mortality of atosiban-initiated standard care were similar to those with placebo-initiated standard care. Given that all patients in this study were eligible for tocolysis and that, in practice, nearly all patients who are eligible for a tocolytic receive one, the benefit of using atosiban is the placebo-like maternal-fetal side effect profile. These observations support the short-term use of this oxytocin receptor antagonist in the treatment of patients in preterm labor with intact membranes. Efficacy and infant outcome data at <28 weeks are inconclusive.
